The Objective Truth: Why in Advanced Cancer, AI “Information” Is Only 10% of the Solution
Even if you know how to use AI tools professionally, in the end, you need a drug in your vein, not a list of results on a computer. Here is…
Even if you know how to use AI tools professionally, in the end, you need a drug in your vein, not a list of results on a computer. Here is…
How to find innovative treatments for metastatic cancer? A short guide for stage 4 patients Patients with metastatic cancer often encounter situations where it seems that "there is nothing more…
🎗 October was Breast Cancer Awareness Month and now it’s behind us. Now, I want to talk to you about what really matters: reality. My name is Nir Erez. I…
Meet Zongertinib (Hernexeos) – a breakthrough drug for patients with HER2‑mutant lung cancer Zongertinib (brand name: Hernexeos) is an innovative oral medication that acts as a selective HER2 receptor inhibitor…
Breakthrough Medical Vaccine for Glioblastoma (GBM): Personalized Life-Extending Immunotherapy A new international study introduces an innovative therapeutic option for glioblastoma (GBM) patients: a personalized vaccine based on the genetic analysis…
🧠 A new treatment for leptomeningeal metastases offers real hope for advanced-stage cancer patients. A groundbreaking study published in Nature Medicine and presented at ASCO 2025 shows promising clinical results…
Metastatic Triple-Negative Breast Cancer: ASCO 2025 Highlights Breakthrough Therapy Metastatic triple-negative breast cancer (TNBC) is one of the most aggressive and difficult-to-treat forms of breast cancer, with limited standard treatment…
We’re happy to share some good news – the well-known and highly respected chef Tomasz Jakubiak has returned to Poland after an extended stay at an oncology hospital in…
*💡 What's This About?* A new study published in BMC Cancer examined an innovative combination of two drugs - Pyrotinib and *Etoposide* in metronomic dosing (low continuous dosing) in patients…
What's This About? A new study published in the prestigious The Lancet Oncology examined an innovative drug called Camizestrant in women with hormone-positive (ER+) and HER2-negative metastatic breast cancer, whose…